Spectral AI, Inc. (MDAI) Earnings Call Transcript
August 11, 2026
Earnings Call Speaker Segments
Thanks, Gary. Hello, everyone, and good afternoon. We appreciate you being here for Spectral AI's conference call covering our financial results for the second quarter of 2026. Speaking today are Vincent Capone, who serves as the company's chief executive officer, and David McGuire, our chief financial officer. Prior to starting, I want to remind all of you that some remarks on this call constitute forward-looking statements as defined under the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, which includes statements about the company's strategy, plans, objectives, initiatives, and financial outlook. In this call, terms such as estimates, projected, expects, anticipates, forecasts, plans, intends, believes, seeks, may, will, should, future, propose, along with variations of these terms or similar expressions or their negatives, are meant to identify forward-looking statements; such forward-looking statements do not guarantee future performance, conditions, or results, and they carry a number of known and unknown risks, uncertainties, assumptions, and other important factors, many beyond the company's control, that might cause actual results or outcomes to diverge from those forward-looking statements. Therefore, listeners should be warned against putting undue reliance on any forward-looking statements, and investors ought to thoroughly weigh the previously mentioned factors along with the other risks and uncertainties outlined in the Risk Factors section of the company's SEC filing, including the registration statement and other documents the company has filed; through these filings, additional significant risks and uncertainties are identified and discussed that might lead actual events and results to differ materially from what those forward-looking statements contain; having said that, I'd now like to hand the call over to Spectral AI's Chief Executive Officer, Vincent Capone. Vince, the floor is yours.
Thank you, Devin, and I appreciate everyone being here with us today. Our earnings release went out this afternoon, and it includes further specifics about how we performed operationally; later today we'll also submit our Form 10-Q to the SEC. Quite a few notable things have happened since our previous conversation. Back in May, we hit a big marker when the FDA granted de novo clearance to our DeepView System for the burn indication — a landmark moment for Spectral AI. That decision confirms how solid our science is and how pioneering our R&D work has been, and it also prepares us for the shift into becoming a commercial company. Looking ahead across the coming years, we'll concentrate mainly on a careful, disciplined rollout in the U.S. and internationally; beyond that, we'll keep growing how familiar clinicians are with the DeepView System via our triage and treatment outcome study initiative, while also broadening our commercial capabilities and infrastructure, pursuing further software and hardware improvements to our technology, and continuing efforts to add more indications in tissue diagnostics — all of which builds the groundwork for lasting, sustainable growth and a bigger footprint in our market. Locating the right talent is a key piece of carrying out that plan. When our previous earnings call began, I introduced David McGuire as our incoming CFO. Today, I'm happy to introduce Darcy Bajko as our new Chief Commercial Officer. Darcy carries substantial market expertise into our company, gained especially during her tenure at Integra and Smith & Nephew, and her recent hiring shows our leadership team keeps getting stronger. Darcy and I will collaborate closely to carry out our commercial strategy, speed up our product launch timeline, and improve coordination among our sales, marketing, market access, and reimbursement strategy. It's a pleasure to have her on board at Spectral AI. Cleared by the FDA without any predicate device, our DeepView system is genuinely the first technology of its kind. It represents the result of over $250 million in nondilutive governmental funding across the past 13 years, plus relentless dedication from our executive and research teams along with partnering clinicians. I want to spend a few minutes discussing our regulatory path and the successes we've achieved so far. Since the FDA's Breakthrough Devices Program started more than a decade ago, close to 1,300 medical devices have satisfied the Center for Devices and Radiological Health's demanding criteria for breakthrough designation. Spectral AI earned that designation in 2018. As of today, our DeepView System stands among just 193 devices — 15% — that have made it through a novel regulatory approval process to reach commercial market authorization via the de novo pathway. Each year, the FDA approves more than 3,000 standard 510(K) submissions, yet it hands out only slightly above 40 de novo authorizations on average — under 2% of the total — which places our technology within an exceptionally narrow class of genuine medical innovation; this uncommon achievement stands as strong evidence of the clinical rigor, disruptive strength, and considerable competitive edge that our DeepView System delivers to the future of wound care. We're eager to bring this product to the burn market throughout the United States and internationally. With the DeepView System, you get an instant determination of whether a burn wound is going to heal by itself or need substantial medical intervention. That removes both undertreatment — which may show up as postponed surgery and a longer stay in the hospital — and over-treatment, or patients enduring a surgery or graft procedure that could have been avoided. More than 340 billion pixels of clinically validated burn images serve as ground truth for our wound assessment capabilities. I can't emphasize enough the competitive moat that this burn biopsy library, together with our patent portfolio, gives our company. These qualities highlight precisely how novel our approach to burn assessment is, while also underscoring what this AI-driven diagnostic imaging platform could achieve in redefining the standard of burn care in triage and treatment; so now that the FDA clearance is in hand, where are we headed? Two complementary revenue streams and a staged adoption path form the basis of our commercial model, which we believe underpins both near-term monetization and long-term recurring growth. When a device is placed, we expect to bring in revenue via capital purchase or lease, and every installation opens the door to recurring annual software and services revenue with a minimum 3-year term that compounds as placements increase. Just as importantly, we grasp the factors that shape revenue timing. In our view, placements at previous clinical sites can progress most quickly and speed up adoption, whereas new installations generally involve a longer capital and procurement cycle. Significant support from our partners at BARDA will benefit the first 30 U.S. installations. Near-term sales and a multi-year commercial runway are what the burn market opportunity provides. With that in mind, though we see a meaningful long-term opportunity across more than 200 high-value facilities, our initial focus will be on deploying up to 30 systems under the BARDA CLIN II portion of our multi-year Project BioShield contract. Through June 30, 2027, under this contract, we will be placing our DeepView System into routine care use at U.S. burn centers, trauma centers, and emergency departments, with some centers supporting our clinical validation work. As part of our international sales strategy, we are currently updating our UKCA burn assessment approval, which we secured in 2024, so that it reflects the improved algorithm, hardware, and software in our FDA cleared device. We expect to receive this expanded UKCA clearance in the fourth quarter of this year, and after that we will begin initial sales and placements of the DeepView System in either the U.K., Australia, or within the Gulf Cooperation Council countries. Over in the U.K., we've kicked off a study covering the head, hands, and feet, which will back a label expansion for the DeepView System in every market. Here at home, we're at the tail end of getting a triage and treatment outcome study underway, designed to show that wound assessments from the DeepView System sharpen surgical precision and speed up treatment decisions, which translates into an improved overall patient care journey and shorter stays for those patients. Our plan is to get this study started in Q4 of 2026, across 12 centers in the United States. Through our cutting-edge diagnostic achievements, we stay unwavering in pursuing better patient care and shorter patient stays. I'd also like to say that we're well capitalized to carry out our strategic priorities. On June 30, 2026, cash on our balance sheet stood at $14 million, alongside a manageable debt maturity and access to more than $60 million in additional non-dilutive funding from BARDA. Looking further out, I'd also stress that we view the DeepView System as a platform technology. As mentioned before, we handed over a prototype of our handheld device to MTEC during the last quarter, under our current Department of War contract. Additionally, we're pursuing expansion of our total body surface area burn calculation. These capabilities leverage the DeepView System's imaging and AI platform to rapidly and objectively measure the burned portion of a patient's body. That would deliver a standardized, data-driven input for triage, fluid resuscitation, and treatment decisions — particularly valuable when situations are complex or involve mass casualties. Our team stays sharply focused on pushing this technology forward, building on these developments to chase potential new indications such as critical limb ischemia, amputations, diabetic foot ulcers, and more. Our team draws energy from our FDA approval and deep motivation from the opportunities ahead. Now that FDA de novo clearance for our DeepView System is behind us, with a clear commercialization roadmap in place and a full bench of experienced leaders carrying out our strategy, I believe we're well positioned to establish Spectral AI as a genuine commercial stage platform technology company in the quarters and years to come. With that, I'll hand things over to David, who will review our financial results for the second quarter of 2026.
Thank you, Vince. As Vince pointed out, Spectral AI just wrapped up a quarter of transition — one showing how we've shifted away from being strictly a development-stage outfit and toward generating commercial sales, and we stay confident that we can keep up our R&D work even while growing this commercial side. Beginning at the top of the income statement, R&D revenue came in at $3.5 million for Q2 '26, down from $5.1 million in Q2 '25. We had expected that drop: our BARDA efforts have reached a cost-sharing stage, and since burn validation is finished and the device has its clearance, we're also sitting between two major study phases. We anticipate BARDA activity will climb further to back this outcome study, mainly during Q4. Money from our other U.S. government contract likewise fell, since we wrapped up the work under our MTEC contract. The BARDA cost share lowers both the revenue and the gross margin we book on this program, and that impact carries on into the follow-on phase. It represents a conscious choice to co-invest with BARDA in the features we believe hold the greatest commercial value. That same arrangement also finances our market entry. BARDA backing covers the first 30 U.S. system placements, meaning the initial installed base gets built with considerable non-dilutive funding behind it. Gross margin for Q2 2026 reached 31.6%, versus 45.2% in Q2 25, which mirrors this cost share. Across the first six months, gross margin stood at 41.8%, compared with 46.4%. Both figures reflect development revenue alone. Our commercial approach works differently: device placement, whether purchased or leased, plus recurring software and service revenue across a minimum three-year term. During the quarter we finished a third-party pricing study, and grounded in that work and early customer conversations, our initial signal is that the market will bear pricing in line with margins far above what our development work delivers today. We'll sharpen that as launch proceeds, but as placements accumulate, we expect a mixed shift to raise our blended gross margin. As commercialization gets underway, we plan to give you clear visibility into our progress. Once sales start, we expect to report system placements and install base, and to separate out recurring software and service revenues once they become meaningful. Operating expenses for Q2 '26 climbed to $5.4 million, up from $4.4 million in Q2 '25. Starting this quarter, we altered how we present operating expenses, splitting out research and development, sales and marketing, and general administrative into three distinct lines, applied retrospectively across all periods shown. We made this change so investors can plainly see where we're putting money ahead of commercialization. On that footing, in Q2 '26 versus Q2 '25, R&D expenses rose $200,000 to $1.7 million, reflecting extra development work on the UKCA mark expansion Vince discussed. Selling and marketing expenses rose $300,000 to $700,000, reflecting launch readiness work that includes the third-party pricing study. General and administrative expenses rose $500,000 to $3.1 million, driven mainly by noncash stock comp tied to equity awards issued during the quarter. If you leave out stock-based compensation, G&A came in basically level compared with a year ago, and we see that as evidence that we're still keeping a tight rein on costs while standing up the commercial side of the business. Other income, in total, came to $300,000 for Q2 '26, versus $5.9 million of other expense in Q2 '25. What drove that shift was mostly the non-cash fair value adjustments tied to our warrant liability. For Q2 '26, net loss came to $4.2 million, or $0.13, on both a basic and diluted per-share basis, against a net loss of $8 million, or $0.31, on both a basic and diluted per-share basis in Q2 2025. That gain came largely from the non-cash swing in warrant fair value, with lower gross profit and greater operating expenses offsetting part of it. Adjusted EBITDA for Q2 '26 reached $3.5 million, versus $1.7 million in Q2 '25. That year-over-year move mostly mirrors reduced gross profit along with more operating investment made in advance of commercialization; turning to our financial condition, cash stood at $14 million on June 30, 2026, against $15.4 million on December 31, 2025. The cash used across the first half mainly reflected ongoing investment in R&D and commercialization efforts, partly offset by the second tranche from our Avenue Capital facility. Regarding that facility, we drew the second tranche of $6.5 million in June, which brings us to the full $15 million commitment. That draw depended on FDA clearance of the DeepView System, and hitting that milestone also pushed our interest-only payment window from a minimum of 15 months out to 24 months, with the facility maturing in March 2028. So no principal payments are due until March '27, which lines up nicely with our $14 million cash position as we finance our commercial launch. We stay committed to disciplined capital allocation as we move forward toward commercialization. Total debt as of June 30, 2026, was $14.9 million, with 32.2 million shares outstanding. All told, with $14 million in cash, no principal payments due through March '27, and ongoing access to substantial nondilutive BARDA funding, we believe we have the resources needed to carry out our commercial launch. We also have our equity facility with Yorkville available should we decide to draw on it. I'm looking forward to engaging with many of you in the coming quarters; with that, I'll hand the call back to Vince.
Thanks, David. Ahead of handing it over for Q&A, I'd like to talk about what we expect in 2026; we're reaffirming our revenue guidance at roughly $18.5 million, and that figure takes into account the impact of the new BARDA funding that started in March of this year. No meaningful amounts from DeepView System sales are factored into this guidance. Having said that, I'll now take questions.
I'd like to begin by asking what the current sales team looks like, or how many reps you believe you'll have to bring on board, and what sort of ramp-up period they'll need to become comfortable with the product for this first rollout of 30 systems? Yes.
Luke, I appreciate the question; so at present, our sales organization truly consists of 2 individuals, our newly appointed chief commercial officer and the person leading our U.K. operations for sales abroad. On the budget side, we've set aside funding for no fewer than 2 more people to support that work. And clearly, I'll be devoting a portion of my own hours to this too, as we aim to help enable installations at a number of the clinical sites along with other sites during the fourth quarter of 2026.
All right, understood. So now that the MTEC contract has wrapped up, what can you tell us about where the handheld device stands, or any reactions to it? And could there be a route toward a subsequent government deal for it?
Good question — honestly, we feel very good about what we've accomplished under our Department of War contract via the MTEC consortium. A prototype went to them earlier this summer, and we completed all remaining items under that MTEC contract. Right now, MTEC is working to figure out what comes next regarding how they'll allocate capital for their 2026 to 2027 budget, which kicks off in October of this year. That said, I'd say our development efforts on the handheld have been pretty impressive. We keep seeing possibilities that we think could open up for the handheld, on the domestic commercial front as well as potentially in certain military uses. I was just at the MHSRS conference last week. There appear to be openings there, particularly considering the current global situation, with possible conflicts and ones already underway.
All right, understood; and finally, when you get ready to kick off that commercial plan and start deploying the initial devices, how are you all establishing ties with hospitals and burn centers? Is BARDA assisting on the connection front, or do they only provide funding to you folks, and what does the timeline for developing those connections appear to be?
Yeah, what I'd say is that building relationships is genuinely an area where I believe we're quite capable in-house. I mean, we've completed two quite sizable trials, the burn study as well as the burn validation study; the burn validation study, as I recall, was the biggest burn trial conducted within the United States. So our clinical group has robust connections to many sites throughout the country. Those connections will be used by us to create an opening for procuring our product; and that work has already begun. We've operated in this field for quite a few years; we hold solid ties throughout the burn community. Our KOLs are strong. We don't — BARDA has been an excellent partner to us through non-dilutive funding, yet that relationship isn't something we leverage, nor do we employ it to gain entry on the commercial side. Our commercial efforts will receive BARDA's backing, and the centers will too, since both of us have; our shared objective has been the same throughout. Across the nation we want to deploy devices so that should a domestic mass casualty event occur, the United States stands ready to treat any of those possible burn victims quickly and, honestly, with thorough diagnosis.
Vince and David, you've now brought a Chief Commercial Officer into the fold, and clearance came through a few months back — so what stands out to you as the biggest obstacles when it comes to deployment?
John, I appreciate that question. So here's the thing — for this organization, deployment is clearly something unfamiliar. Darcy brings a lot of experience to it, and so do other members of our team, but when we have to clear the procurement stage in centers where our relationships aren't strong, that stretches the procurement window out longer, since we're navigating these new AI committees and the procurement process overall. It's a learning process for us, though at certain centers where KOL backing runs deep, our confidence is high that procurement will move along at a fairly quick pace. At others, what we're finding is that we have to navigate the procurement side along with the cybersecurity and AI component committees too. That's what we're sorting through. Even so, our confidence is strong that we can hit the broader timeline, plus the rollout timeline we've set up internally.
All right. You folks brought up before that perhaps a few deployments could happen in the Middle East, so I'd like to know where that relationship stands now. Beyond the U.K., Australia, and the United States, are there additional regions showing interest?
Absolutely, John — that's an excellent thing for us to address, isn't it? We — what I observe is that time has been invested with devices over in Australia as well as the U.K., on an evaluation basis. Naturally, our expectation is that they'll be the earliest to take up this technology. I don't want to, you know, get over my skis on any of this, but other parts of the globe hold opportunities where we believe there might be some low-hanging fruit. Our experience in the U.K. has been great. In Australia, it's been very good. I'd be remiss if I didn't think that those combined with one or two centers in the U.K. will be the first international installations. Others may exist, but that's what we view as, sort of, the near-term window. And honestly, I'm excited to announce that hopefully at some point in 2026.
Alright, and my final question concerns, I suppose, the nature of the parties that are interested. Do most or any of the facilities already own some kind of burn device, such as Laser Doppler imaging, or do they possess no technology whatsoever? I'm curious about who shows more interest — a party acquainted with that sort of technology, or one that has nothing?
Well, my argument would be that each burn center across the United States either possesses nothing at all, or possesses a technology so outdated that putting our device in place represents a major leap forward in diagnostic imaging for every one of these sites; and I'm glad you brought up LDI imaging devices; that's fairly common, primarily common in the U.K. Adoption in the United States is very limited; we're eager to introduce our technology at these centers. The clinicians who took part specifically in our burn validation study, they grasp that technology and what it can do. Honestly, we're eager to begin and to place these at these centers, both to safeguard the United States in the event of a mass casualty situation, and also to enhance patient care. And we've spent 17 years in this game. We're eager to enhance patient outcomes and patient care. If it isn't obvious, I'm rather eager about where we're headed.
Thanks, Gary. To wrap up, I want to express gratitude once more to those who hold shares in our company for standing behind us. What's coming next has us energized. I'd also like to say again how grateful we are for the efforts of our clinician support team and for the partnership we share with them—and above all, we're thrilled that patients nationwide and globally will soon be helped by this pioneering technology. I appreciate everyone joining us and taking an interest in what we do. Enjoy your evening.
That brings this call to a close. We appreciate everyone joining us for today's presentation. You're free to hang up at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Spectral AI, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Spectral AI, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.